However, many clinical trials have demonstrated that anti-angiogenic agents enhanced clinical efficacy when combined with conventional chemotherapy or targeted cancer agents such as erlotinib, an epidermal growth factor receptor (EGFR) TKI [12]. Here, EGFR is linked to cancer.